{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IMBRUVICA+%28Treatment+A%29&page=4", "query": { "intervention": "IMBRUVICA (Treatment A)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 169, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IMBRUVICA+%28Treatment+A%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IMBRUVICA+%28Treatment+A%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T06:01:45.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02548962", "title": "Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2016-03", "completion_date": "2018-06-13", "has_results": true, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02548962" }, { "nct_id": "NCT01880567", "title": "Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CCND1 Positive", "CCND2 Positive", "CCND3 Positive", "CD20 Positive", "Mantle Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2013-07-15", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01880567" }, { "nct_id": "NCT03323151", "title": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle-Cell Lymphoma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-08-13", "completion_date": "2023-09-07", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 14, "location_summary": "Atlanta, Georgia • Augusta, Georgia • Urbana, Illinois + 11 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03323151" }, { "nct_id": "NCT02514083", "title": "A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2015-12-09", "completion_date": "2034-10-23", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02514083" }, { "nct_id": "NCT01752426", "title": "Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Heavy Water (2H2O)", "type": "OTHER" }, { "name": "PCI-32765", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2012-12-17", "completion_date": "2018-08-09", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752426" }, { "nct_id": "NCT04694560", "title": "A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "CLL", "SLL", "CLL/SLL", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Treatment Free Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-12-22", "completion_date": "2023-03-06", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 2, "location_summary": "Monroe, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Monroe", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04694560" }, { "nct_id": "NCT02309580", "title": "Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Lymphoma", "Relapsed and Refractory T-cell Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-01", "completion_date": "2023-05-08", "has_results": false, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 2, "location_summary": "New York, New York • Columbus, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02309580" }, { "nct_id": "NCT03198026", "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Nodal Marginal Zone Lymphoma", "Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Nodal Marginal Zone Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Nodal Marginal Zone Lymphoma", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Indolent Non-hodgkin Lymphoma", "Stage II Splenic Marginal Zone Lymphoma", "Stage III Splenic Marginal Zone Lymphoma", "Stage IV Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-02-20", "completion_date": "2032-02-20", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03198026" }, { "nct_id": "NCT01820936", "title": "A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Sequence 1: PCI-32765", "type": "DRUG" }, { "name": "Sequence 2: PCI-32765", "type": "DRUG" }, { "name": "Sequence 3: PCI-32765", "type": "DRUG" }, { "name": "Sequence 4: PCI-32765", "type": "DRUG" }, { "name": "Sequence 5: PCI-32765", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2013-03", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-07-15", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 1, "location_summary": "Neptune City, New Jersey", "locations": [ { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01820936" }, { "nct_id": "NCT02940301", "title": "Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 18, "start_date": "2016-12-20", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-10T06:01:45.275Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Columbus, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02940301" } ] }